US DoJ summons Sun Pharma over generic drug prices
The Dollar Business Bureau India’s largest drug maker, Sun Pharma, received summons over pricing and marketing of generic drugs from the US Department of Justice on Saturday. The subpoena surfaced amidst the probe initiated by US regulators into the matter of price rise of generic drugs over the past few years. However, the pharma major stated that the move will not affect the company adversely. The antitrust division of the court had asked the US arm of Sun Pharma to submit documents disclosing its employee and corporate records and communication with its competitors. Besides Sun Pharma, Dr. Reddy’s Lab, Allegran Plc also received summons from the US regulators in the past seeking pricing details. However, the details of the products involved were not disclosed. ...
Sun Pharma gets USFDA approval for anti-cancer drug Gleevec
Gleevec tablets are used for the treatment of chronic myeloid leukemia - a rare form of blood cancer The Dollar Business Bureau The Sun Pharma subsidiary was the first to file an ANDA for generic Gleevec with a para IV certification for 180-days marketing exclusivity in the US. Sun Pharmaceutical Industries Ltd. on Friday announced that one of its subsidiaries has received final approval from USFDA for its Abbreviated New Drug Application (ANDA) for generic version of Gleevec, Imatinib Mesylate tablets 100mg and 400mg. Imatinib Mesylate tablets, 100 mg and 400 mg are therapeutic equivalents of Novartis Gleevec tablets, Sun Pharmaceutical said in a statement. Gleevec tablets are used for the treatment of chronic myeloid leukemia- a rare form of blood cancer.These tablets have ...
